- Home
- CUE vs SLGL Comparison
CUE vs SLGL Comparison
Compare CUE & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- SLGL
- Stock Information
- Founded
- CUE 2014
- SLGL 1997
- Country
- CUE United States
- SLGL Israel
- Employees
- CUE N/A
- SLGL N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- SLGL Health Care
- Exchange
- CUE Nasdaq
- SLGL Nasdaq
- Market Cap
- CUE 61.1M
- SLGL 69.1M
- IPO Year
- CUE 2018
- SLGL 2018
- Fundamental
- Price
- CUE $0.56
- SLGL $36.00
- Analyst Decision
- CUE Strong Buy
- SLGL Strong Buy
- Analyst Count
- CUE 2
- SLGL 1
- Target Price
- CUE $3.00
- SLGL $50.00
- AVG Volume (30 Days)
- CUE 394.8K
- SLGL 18.5K
- Earning Date
- CUE 11-12-2025
- SLGL 11-20-2025
- Dividend Yield
- CUE N/A
- SLGL N/A
- EPS Growth
- CUE N/A
- SLGL N/A
- EPS
- CUE N/A
- SLGL N/A
- Revenue
- CUE $7,100,000.00
- SLGL $18,970,000.00
- Revenue This Year
- CUE N/A
- SLGL N/A
- Revenue Next Year
- CUE N/A
- SLGL N/A
- P/E Ratio
- CUE N/A
- SLGL N/A
- Revenue Growth
- CUE N/A
- SLGL 62.04
- 52 Week Low
- CUE $0.54
- SLGL $4.01
- 52 Week High
- CUE $1.75
- SLGL $52.26
- Technical
- Relative Strength Index (RSI)
- CUE 28.56
- SLGL 52.52
- Support Level
- CUE $0.57
- SLGL $32.51
- Resistance Level
- CUE $0.62
- SLGL $36.40
- Average True Range (ATR)
- CUE 0.08
- SLGL 3.40
- MACD
- CUE -0.01
- SLGL 0.07
- Stochastic Oscillator
- CUE 0.53
- SLGL 65.65
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.